Stay informed about the latest in biotech by signing up for our newsletter. This week, concerns were raised about data gaps in MDMA-assisted therapy trials, potentially affecting FDA approval. The efficacy of Ozempic in preventing death in diabetes and chronic kidney disease patients was also highlighted. Furthermore, BIO, a drug industry lobbying group, faced challenges with multiple leadership changes. FDA advisers recommended Guardant’s blood-based colon cancer test for approval. Additionally, J&J reported mixed data on a radiopharmaceutical ahead of ASCO, and Nimbus outlined hopes for their next-gen immunotherapy drug after a $4 billion deal with Takeda. Stay tuned for more updates at this year’s ASCO meeting.
Source link
BIO chaos, Ozempic, MDMA therapy, Guardant
